The pharmacokinetics of ceftaroline in patients with hepatic impairment have not been established.

No studies have so far been performed in patients with severe hepatic impairment.

A dose reduction is recommended in patients with hepatic impairment.

Those with hepatic impairment should receive a half dose.

Darunavir should be used with caution in patients with hepatic impairment.

The drug is contraindicated in patients who have severe hepatic impairment.

The drug has not been tested in patients with severe hepatic impairment.

Thus, reduced doses may be used in renal and hepatic impairment.

It is also contraindicated in severe renal or hepatic impairment.

It is contraindicated in hepatic impairment or liver disease expected to have any impact on survival.